Barclays has maintained an equal weight rating for Bayer, setting a price target of 22 euros ahead of the company's Q1 earnings report. Despite ongoing litigation and a slight dip in Crop Science revenue projections, analysts express confidence in Bayer's cash flow and strategic plans, with expected sales of 13.53 billion euros and EPS of 2.30 euros, slightly below Bloomberg's consensus estimates. Bayer's resilience amid legal challenges highlights its adaptability and commitment to maintaining guidance, reassuring investors about potential market volatility.